BlackRock Health Sciences Opps Svc (SHISX)
63.65
+0.39
(+0.62%)
USD |
Mar 30 2023
Key Stats
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.14% | 8.567B | 0.29% | 51.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -1.031B | -4.64% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term growth of capital. The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | SHSAX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | BlackRock |
| Prospectus Benchmark Index | |
| Russell 3000 Ind/HC TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Erin Xie | 19.60 yrs |
| Jeff Lee | 2.75 yrs |
| Xiang Liu | 2.75 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
97
-1.031B
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 30, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 30, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 7.77% | 472.42 | 0.50% |
| Eli Lilly and Co | 5.19% | 343.34 | 0.78% |
| Thermo Fisher Scientific Inc | 4.79% | 576.22 | 2.35% |
| Merck & Co Inc | 4.45% | 106.38 | 0.43% |
| Boston Scientific Corp | 3.59% | 50.02 | 0.85% |
| Danaher Corp | 3.47% | 251.94 | 0.85% |
| Stryker Corp | 3.08% | 285.32 | 1.64% |
| Abbott Laboratories | 3.08% | 101.26 | 2.20% |
| AbbVie Inc | 3.05% | 159.35 | 0.91% |
| Amgen Inc | 2.75% | 241.77 | 0.11% |
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term growth of capital. The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | SHSAX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | BlackRock |
| Prospectus Benchmark Index | |
| Russell 3000 Ind/HC TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Erin Xie | 19.60 yrs |
| Jeff Lee | 2.75 yrs |
| Xiang Liu | 2.75 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-30-23) | 0.29% |
| 30-Day SEC Yield (12-31-16) | Upgrade |
| 7-Day SEC Yield (3-30-23) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 24.38 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of February 28, 2023
Fund Details
| Key Dates | |
| Inception Date | 1/28/2005 |
| Last Annual Report Date | 5/31/2022 |
| Last Prospectus Date | 9/28/2022 |
| Share Classes | |
| BHSRX | Retirement |
| SHSAX | A |
| SHSCX | C |
| SHSKX | Retirement |
| SHSSX | Inst |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |